 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- || ASP3662 / Astellas
Clinical, PK/PD data, Journal: Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β-HSD1 Inhibitor, in Healthy Young and Elderly Subjects. (Pubmed Central) - Jul 5, 2020
A marked dissociation between pharmacokinetics and pharmacodynamics was observed after single, but not multiple doses of ASP3662. ASP3662 was generally safe and well tolerated.
- | ASP3662 / Astellas
Journal: A Novel F-Labeled Radioligand for Positron Emission Tomography Imaging of 11β-Hydroxysteroid Dehydrogenase (11β-HSD1): Synthesis and Preliminary Evaluation in Nonhuman Primates. (Pubmed Central) - May 31, 2020
In monkey brain, [F]AS2471907 displayed high uptake and heterogenous distribution, while administration of the 11β-HSD1 inhibitor ASP3662 significantly reduced uptake, thus demonstrating the binding specificity of [F]AS2471907. Given the longer half-life of F-18 and feasibility for central production and distribution, [F]AS2471907 holds great promise to be a valuable PET radiotracer to image 11β-HSD1 in the brain.
- | ASP3662 / Astellas
Journal: IMAGING THE ENZYME 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 WITH POSITRON EMISSION TOMOGRAPHY: EVALUATION OF THE NOVEL RADIOTRACER C-AS2471907 IN HUMAN BRAIN. (Pubmed Central) - Apr 14, 2020
Given the longer half-life of F-18 and feasibility for central production and distribution, [F]AS2471907 holds great promise to be a valuable PET radiotracer to image 11β-HSD1 in the brain. Two subjects underwent an additional scan after blockade with the selective and high-affinity 11β-HSD1 inhibitor ASP3662 to evaluate C-AS2471907 nondisplaceable distribution volume...C-AS2471907 has a very high fraction of specific binding in vivo in humans, and reasonable within-day reproducibility of binding parameters.
- | ASP3662 / Astellas
Preclinical, Journal: Analgesic effect of ASP3662, a novel 11β-HSD1 inhibitor, in rat models of neuropathic and dysfunctional pain. (Pubmed Central) - Oct 18, 2019
These results indicate that ASP3662 is a potent, selective and CNS-penetrable inhibitor of 11β-HSD1. The effects of ASP3662 suggest that selective inhibition of 11β-HSD1 may be an attractive approach for the treatment of neuropathic and dysfunctional pain, such as that observed in fibromyalgia.
- | ASP3662 / Astellas
Trial completion: A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 (clinicaltrials.gov) - Jun 28, 2016
P1, N=18, Completed, Sponsor: Astellas Pharma Global Development, Inc.
The effects of ASP3662 suggest that selective inhibition of 11β-HSD1 may be an attractive approach for the treatment of neuropathic and dysfunctional pain, such as that observed in fibromyalgia. Recruiting --> Completed
- | ASP3662 / Astellas
Phase classification, Enrollment change, Trial termination, Trial primary completion date: Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Jun 10, 2016
P2a, N=116, Terminated, Sponsor: Astellas Pharma Global Development, Inc.
Recruiting --> Completed Phase classification: P2 --> P2a | N=210 --> 116 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> May 2016; The study was terminated due to futility analysis.
- ASP3662 / Astellas
Trial primary completion date: A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 (clinicaltrials.gov) - Oct 28, 2015
P1, N=18, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Phase classification: P2 --> P2a | N=210 --> 116 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> May 2016; The study was terminated due to futility analysis. Trial primary completion date: Oct 2015 --> Apr 2016
- ASP3662 / Astellas
Trial primary completion date: A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 (clinicaltrials.gov) - Jul 10, 2015
P1, N=18, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Jun 2015 --> Oct 2015
- |||| ASP3662 / Astellas
Enrollment open: Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Jun 20, 2015
P2, N=210, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial primary completion date: Jun 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- ASP3662 / Astellas
Trial primary completion date: A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 (clinicaltrials.gov) - Mar 14, 2015
P1, N=18, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Jun 2015
- ||||| ASP3662 / Astellas
New P2 trial: Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Feb 26, 2015
P2, N=210, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- ASP3662 / Astellas
Trial primary completion date: A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 (clinicaltrials.gov) - Dec 5, 2014
P1, N=18, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial primary completion date: Feb 2015 --> Jun 2015 Trial primary completion date: Nov 2014 --> Feb 2015
- | ASP3662 / Astellas
New P1 trial: A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 (clinicaltrials.gov) - Jul 18, 2014
P1, N=18, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.